Cleland J G, Dargie H J
Department of Cardiology, Western Infirmary, Glasgow, UK.
Eur Heart J. 1987 Aug;8 Suppl D:65-9. doi: 10.1093/eurheartj/8.suppl_d.65.
In a group of 62 patients with chronic heart failure 29% developed ventricular tachycardia during exercise testing. The two-year survival of this group was only 22%, compared to 55% in those not demonstrating ventricular tachycardia (P less than 0.01). In a double-blind cross-over study against placebo, with three-month treatment periods, amiodarone, in a dose of 200 mg day-1, was found effectively to suppress ventricular arrhythmias during exercise and in the immediate post-exercise period. Exercise performance was not impaired. Amiodarone may be useful in preventing life-threatening arrhythmias in patients with heart failure.
在一组62例慢性心力衰竭患者中，29%在运动试验期间出现室性心动过速。该组患者的两年生存率仅为22%，而未出现室性心动过速的患者为55%（P<0.01）。在一项针对安慰剂的双盲交叉研究中，治疗期为三个月，发现剂量为每日200毫克的胺碘酮能有效抑制运动期间及运动后即刻的室性心律失常。运动能力未受损害。胺碘酮可能有助于预防心力衰竭患者发生危及生命的心律失常。
